In Vitro Diagnostic Industry in China - Clinical Chemistry XVI

4.    Future Development Trend

Presently, the biochemical diagnosis industry is facing fierce competitions in the price, policies, and development models (centralized procurement, rich production line). By sticking to the R&D route of high-quality products, increasing investment in high-end biochemistry analyzer R&D, the import substitution is completed; at the same time, by reducing the reagent costs and steadily advancing the market segments, the enterprise can maintain stable development and expand the market capacity, facilitating the industrial development.

4.1 “Intensive Cultivation”

For a long time, the domestic IVD market follows the imported brands and it is difficult to break the import monopoly. With the development of technology, the influence of fierce competition in the biochemical market has increased. Although the growth rate of the traditional biochemical diagnosis market has declined, the biochemical diagnosis has the natural advantages of time and cost for the testing of specific items and will not be replaced. By referring to the mature market structure of foreign countries, the biochemical diagnosis will occupy a certain market share.

After decades of extensive development, the key to the development of biochemical diagnosis is to adhere to the route of R&D of high-quality products, improve product stability, and master the core preparation technology of raw materials. The biochemical diagnosis should focus on the improvement of the product quality of the original testing items and the development of new testing items as a result of technological progress. For example, in the R&D of new products, with the application of latex-enhanced immunoturbidimetry and colloidal gold-enhanced immune technology, the detection sensitivity of the automatic biochemistry analyzers has been greatly improved, so that some items that are originally tested by the ELISA can be completed in the fully automatic biochemistry analyzer. The specific test items are based on the accuracy, cost and time, rather than only considering the advancement of technologies. Generally, companies should consider the product lines, marketing modes, and building high-quality items in making choices.

Through comprehensively sorting out the domestic biochemical industry chain, identifying the advantages and bottleneck in the industry chain, and making supplement, the stability of the supply chain is strengthened. In addition, the innovation chain of the industry is deployed around the industry chain in each stage of the entire life cycle of the product, to reasonably allocate the talents, funds and resources to each link of the product cycle. Moreover, the investment in R&D is increased, the combination of production, education, and research is further deepened, the platforms and human resources of universities and research institutions are utilized, favorable policies are issued, the income distribution of scientific researchers in research results is improved, the IP transformation efficiency is improved, and the refined quality services are implemented, which are important measures to boost the brand growth. A digital service platform will be built, to digitize offline entities online, integrate regional resources such as space, talent, capital, and policies, and expand the scope of services through virtual aggregation of online service resources. The needs of enterprises will be quickly responded to achieve precise resource matching. The industrial agglomeration is continuously promoted, the industrial innovation capability is enhanced, and the cost reduction and efficiency increase of the regional industrial development are promoted, to achieve the precise industrial governance.

Last: In Vitro Diagnostic Industry in China - Clinical Chemistry XV​

Next: In Vitro Diagnostic Industry in China - Clinical Chemistry XVII​